Ivana Mikačić

Ivana Mikačić

Auto-generated profile, based on publicly available information

Ivana Mikačić

Unit for Clinical Pharmacology, Department of Internal Medicine, University Hospital “Sveti Duh”, Zagreb, Croatia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2018 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
IMIvana Mikačić
Ivana Mikačić
RBRobert Belužić
Robert Belužić
OVOliver Vugrek
Oliver Vugrek
ĐPĐuro Plavljanić
Đuro Plavljanić

4 October 2024 in Clinical Medicine
Verified
Journal Article
Open access
IMIvana Mikačić
Ivana Mikačić
NMNikolina Marić
Nikolina Marić
Atypical hemolytic-uremic syndrome (aHUS) is a rare disease associated with uncontrolled activation of the alternative complement pathway, leading to thrombotic microangiopathy (TMA). Early diagnosis and treatment with eculizumab, a monoclonal antibody targeting the complement component C5, are crucial to improve outcomes and prevent renal failure and mortality. Current recommendations include lifelong eculizumab therapy, yet this practice presents challenges including high treatment costs and increased infection risks from prolonged complement inhibition. We hypothesize that a personalized eculizumab dosing strategy tailored to individual patient responses could optimize therapy, reduce costs, and improve safety. This hypothesis was evaluated through a presentation of a patient who was managed with a specific eculizumab treatment approach. The patient's condition improved significantly, allowing for a gradual reduction in eculizumab dosage based on clinical response and drug level monitoring. Throughout treatment, the patient's complement activity and eculizumab levels were closely monitored, showing that lower doses maintained therapeutic efficacy without evident TMA recurrence. This case supports the feasibility of transitioning from fixed regimens to personalized dosing strategies in managing aHUS. Such approaches could mitigate the risks and costs associated with lifelong therapy while maintaining disease control, especially considering the variability in relapse risk among different genetic mutations. This personalized treatment model might significantly impact the management of aHUS, aligning clinical care with individual patient needs and economic considerations. Further research should relate drug pharmacokinetics/pharmacodynamics to clinical/genetic setting to identify milestones of individual patient treatment approach.

23 July 2025 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
IMIvana Mikačić
Ivana Mikačić
HMHrvačić Martina
Hrvačić Martina
BDBarišić Dunja
Barišić Dunja
MKMajstorović Barać Karolina
Majstorović Barać Karolina
KMKurtov Marija
Kurtov Marija
ŠDŠprem Dragica
Šprem Dragica

2 December 2025 in Kidney360
Verified
Journal Article
Open access
IMIvana Mikačić
Ivana Mikačić
Antun KoprivanacAntun Koprivanac
Antun Koprivanac
MCMarijana Coric
Marijana Coric